Sana Biotechnology, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
SANA$2.47+4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net loss | $(266,759) | $(283,255) | $(269,476) |
| Other comprehensive income (loss): | |||
| Unrealized gain (loss) on marketable securities, net | 74 | 4,267 | (2,961) |
| Total comprehensive loss | $(266,685) | $(278,988) | $(272,437) |
Sana Biotech nology, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.